Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Zoetis Inc (ZTS) Price & Performance

First Trust NASDAQ 100 Technology Index FundTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ 100 Technology Index Fund vs Zoetis Inc — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $310.91, while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while First Trust NASDAQ 100 Technology Index Fund pays none, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

QTECZTS
Sector
Broad Market / FactorHealth
52-Week High
$335.74$150.61
52-Week Low
$207.03$71.91
Market Cap
$30.40B
Enterprise Value
$37.96B
Dividend Yield
2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ 100 Technology Index Fund

QTEC trades at $311.57, down 0.22% with neutral technical signals. The ETF shows bearish moving averages but neutral oscillators, with key support at $310 and resistance at $313. Recent coverage highlights its equal-weighted tech exposure and liquidity advantages over peers like RSPT, with software appearing undervalued relative to historical averages according to Seeking Alpha analysis.

The technology sector ETF offers diversified exposure but faces typical sector volatility risks. Current technical positioning suggests limited near-term momentum, while fundamental analysis indicates selective value opportunities within the portfolio components. Market sentiment remains balanced between growth potential and valuation concerns in the tech space.

Zoetis Inc

Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.

The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Trust NASDAQ 100 Technology Index Fund

QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.

Read more on QTEC

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS